We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Drug Resistant Bacterial Strains Impact Infectious Disease Diagnostic Segment

By LabMedica International staff writers
Posted on 02 Sep 2009
The most substantial growth in the US $8.4 billion market for infectious disease diagnostics will be in molecular testing. More...
The expanding population of drug resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA) and multidrug resistant Mycobacterium tuberculosis (TB) will vindicate the use of nucleic acid-based tests (NAT).

The two traditional methods, culture-based assays and immunoassays, are becoming increasingly inadequate for infectious disease testing. Emergence of drug-resistant bacterial strains means that immunoassays have no analytical potential. Culture-based assays for bacterial susceptibility/sensitivity, although inexpensive, are slow and often difficult.

Laboratories are still largely equipped with immunoassay instrumentation, but not all have access to a thermal cycler or the expertise to perform a molecular MRSA test. According to a report by life science market research company Kalorama Information, (New York, NY, USA) replacement of current assays with molecular-based tests will be slow because of the recession. Therefore, both culture-based assays and immunoassays will remain in use for infectious disease tests that do not require rapid turn-around or are otherwise difficult to perform. The cost of nuclear acid-based NAT assays, which are not usually analyzed outside the hospital laboratory, is high at around $25-$35, while selective media cost about $5 a plate.

"Relevancy is established through significantly improved efficacy and not marginal improvement,” said Bruce Carlson, publisher of Kalorama Information. "NAT testing can be put to many uses, but what will get it into more labs is its role in determining the genetic differences that make a bacterial strain […..] drug resistant, with results in 2-4 hours.”

NAT testing will allow physicians to rapidly select combination therapeutics for infections caused by resistant organisms. In viral applications, for example in human immunodeficiency virus (HIV) infection, NAT testing successfully detected drug resistance that developed in response to therapy.

Related Links:
Kalorama Information


New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Portable Electronic Pipette
Mini 96
New
Silver Member
PCR Plates
Diamond Shell PCR Plates
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Over 100 new epigenetic biomarkers may help predict cardiovascular disease risk (Photo courtesy of 123RF)

Routine Blood Draws Could Detect Epigenetic Biomarkers for Predicting Cardiovascular Disease Risk

Cardiovascular disease is a leading cause of death worldwide, yet predicting individual risk remains a persistent challenge. Traditional risk factors, while useful, do not fully capture biological changes... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.